What happened
Boehringer Ingelheim reported the first big Phase 3 results for survodutide, its two-in-one drug that acts on both the GLP-1 and glucagon receptors (a different second target than the GIP used by Mounjaro and Zepbound).
In the SYNCHRONIZE-1 trial, adults with obesity but without type 2 diabetes lost up to 16.6% of their body weight over 76 weeks, compared with 3.2% on placebo, along with improvements in their wider metabolic health.
Where it fits
That number lands survodutide squarely in the modern range: more than semaglutide's roughly 15%, in the neighbourhood of tirzepatide's 21%, and below retatrutide's headline 30%. It is not the biggest figure in the field. It is another genuinely effective, soon-to-be-available option.
And that is the quietly good news. The story of GLP-1s in 2026 is not one winner; it is a growing shelf of effective drugs, each with a slightly different mix of effects and side effects.
What it means for you
A wider shelf is good for you, because the best drug is the one you can stay on. The one that controls your appetite without nausea you can't manage, that your insurance covers, that fits your life, beats the one with the most impressive trial slide that you quit in month two.
If you and your prescriber ever weigh a switch, the decision goes best when it is built on your own data, not memory. Our piece on how the major drugs compare lays out the trade-offs in plain terms.
